Pricing Log in Create free account

Celldex Therapeutics, Inc. (CLDX) vs NewAmsterdam Pharma Company N.V. (NAMS)

Celldex Therapeutics, Inc. and NewAmsterdam Pharma Company N.V. are both Biotechnology companies. Celldex Therapeutics, Inc. and NewAmsterdam Pharma Company N.V. are of similar size ($2.3B and $2.2B). NewAmsterdam Pharma Company N.V. grew revenue faster over the last twelve months: −26.4% against −88.3%. NewAmsterdam Pharma Company N.V. has the higher net margin (−789.9% vs −33,883.8%) and the lower return on invested capital (−23.1% vs 0.00%). Across the 16 metrics below, NewAmsterdam Pharma Company N.V. leads on 12 and Celldex Therapeutics, Inc. on 4.

Valuation

Metric CLDX NAMS Biotechnology median
P/E n/m n/m 10.26
P/S 2,497.55 91.08 9.18
P/B 3.10 3.75 2.05
Price to free cash flow n/m n/m 24.81
EV/EBITDA n/m n/m 0.65
EV/Sales 1,691.39 66.59 8.98
Earnings yield (15.28%) (8.88%) (34.89%)
Free cash flow yield (10.93%) (6.39%) (24.52%)

Profitability

Metric CLDX NAMS Biotechnology median
Gross margin 100.00% 100.00% 65.16%
Operating margin (36,733.82%) (900.07%) 0.00%
Net margin (33,883.77%) (789.94%) 0.00%
Free cash flow margin (27,294.81%) (581.64%) 0.00%
Return on equity (43.88%) (30.16%) (50.12%)
Return on assets (40.76%) (27.79%) (45.60%)
Return on invested capital 0.00% (23.13%) 0.00%

Growth

Metric CLDX NAMS Biotechnology median
Revenue growth (TTM) (88.27%) (26.41%) 6.26%
EPS growth (last fiscal year) (59.18%) 32.81% 29.88%
Revenue growth, 5-year CAGR (26.93%) — 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric CLDX NAMS Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 11.82 11.76 4.89
Net debt to EBITDA 1.78 2.83 1.01

Dividend

Metric CLDX NAMS Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric CLDX NAMS Biotechnology median
Market cap 2.22b 2.26b 172.11m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack